<DOC>
	<DOCNO>NCT00427336</DOCNO>
	<brief_summary>Primary Objectives : 1 . To determine feasibility toxicity employ purine-analog base conditioning allogeneic donor stem cell transplantation patient severe aplastic anemia ( AA ) . 2 . To determine engraftment kinetics degree chimerism achieve strategy .</brief_summary>
	<brief_title>Purine Analog-Based Conditioning Patients With Severe Aplastic Anemia</brief_title>
	<detailed_description>Before treatment start , patient bone marrow check lung , heart , kidney test . Patients study receive drug fludarabine , cyclophosphamide , antithymocyte globulin vein previously insert plastic catheter extend large chest vein . Fludarabine give daily four day , cyclophosphamide give daily four day , antithymocyte globulin give daily four day ( three day relate donor transplant ) . Two day last dose cyclophosphamide , donor marrow stem cell infuse catheter ( thin plastic tube ) . Drugs give low chance allergic reaction stem cell . Patients also get shot filgrastim ( drug help white blood cell growth ) antibiotic mouth . The blood cell count fall low level first 2 week patient may need transfusion red blood cell platelet . The chemotherapy give hospital . After infusion stem cell , patient monitor hospital . They later closely followed outpatient require remain Houston area three month transplant . Drugs ( cyclosporine methotrexate ) low chance graft-versus-host disease give . Cyclosporine give continuous infusion start 2 day transplantation . Methotrexate give catheter Days 1 , 3 , 6 11 transplantation . Cyclosporine give pill patient able swallow . Cyclosporine continue less 6 month transplantation gradually stop . The drug tacrolimus may use instead cyclosporine . Blood , urine , bone marrow , x-ray exam do need monitor result bone marrow transplantation . Patients may require blood platelet transfusion . Blood test do daily hospitalize several time week blood count recover . Bone marrow aspiration biopsy perform transplant , donated cell show sign engraftment , time next 1 3 year . They do evaluate growth transplant marrow , possible recurrence malignancy , recovery immunity . If treatment prove unsuccessful three first ten patient , study stop . This investigational study . The FDA approve drug study indication . Up 30 patient treat study . All enrol M.D . Anderson .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients 70 year age diagnosis severe AA ( Camitta et al. , 1979 ) match unrelated donor unresponsive IS relapse initial response IS . Patients diagnosis SAA human leukocyte antigen ( HLA ) compatible sibling donor eligible 40 year age older ( age 70 ) regardless whether receive IS . Patients primary secondary graft failure follow autologous allogeneic stem cell transplant eligible . Patients must serum bilirubin 2 mg/dl less , serum creatinine &lt; 2.0 mg/dl , symptomatic cardiac pulmonary disease PS 2 . Life expectancy severely limited concomitant illness ( &gt; 12 week ) . Left ventricular ejection fraction &gt; 40 % , uncontrolled arrhythmia symptomatic cardiac disease . Forced Expiratory Volume 1 Second ( FEV1 ) , Forced Vital Capacity ( FVC ) Carbon Monoxide Diffusing Capacity ( DLCO ) &gt; 40 % . No symptomatic pulmonary disease . Negative pregnancy test . Patients must HLAcompatible related unrelated donor willing donate marrow rhGCSFmobilized peripheral blood stem cell . In event transplant match unrelated donor , highresolution allele match HLAA , B , C , DRB1 DQB1 ( `` 10 10 match '' ) prefer . However , oneantigen mismatch ( `` micromismatch '' ) also consider acceptable matching ( `` 9 10 match '' ) . Patients must sign informed consent . In event pediatric patient ( i.e. , minor ) , consent provide guardian/parent . Lack clonal cytogenetic abnormality associate acute myeloid leukemia ( AML ) , myelodysplastic syndrome ( MDS ) hematologic malignancy . Life expectancy le 8 week . Inability provide inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Severe Aplastic Anemia</keyword>
	<keyword>Bone Marrow Failure</keyword>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Antithymocyte Globulin</keyword>
	<keyword>SAA</keyword>
	<keyword>ATG</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Thymoglobulin</keyword>
</DOC>